咨询客服 咨询客服

Structural changes and trade competitiveness in the Indian pharmaceutical industry in product patent regime

Abstract:
This paper aims to present structural changes and trade competitiveness in Indian pharmaceutical industry in pre and post product patent regime. The study shows the impact of product patent on market structure, ownership, trade, revealed comparative advantage, R&D and mergers and acquisitions.,The study is based on secondary data and extensive relevant conceptual and empirical literature review.,The study finds that this oligopoly Indian dominant pharmaceutical industry has many challenges ahead such as in R&D expenditure, patent expiration of many major drugs manufactured in Ireland, growing competition in generic global market, bulk drugs dependence on China, rise in the number of M&As, rising costs of new drug discovery and tightening safety and efficacy testing requirements. The smaller firms are likely to act as the contract manufacturers for medium and bigger companies at a lower value chain. The Normalised Revealed Comparative Advantage (NRCA) index was calculated for top exporters of pharmaceutical. It was found that NRCA index of IPI has shown deterioration from 1996 to 2005 and thereafter, improvement except in the year 2009. Switzerland, Belgium and Ireland are the top three countries in NRCA index, which are followed by Germany, the UK and France.,It attempts to capture recent trends in market structure, comparative advantage indices, R&D, trade, M&A and ownership, especially in new IPR regime. There is a dearth of studies providing detailed analyses of India’s comparative advantage vis-a-vis other leading exporters of pharmaceutical products in the world. The paper would be of value to practitioners and scholars interested in structural changes of IPI, especially in product patent regime. The findings have significant implications for managers and government for future policymaking.
Author Listing: Varun Mahajan
Volume: 13
Pages: 21-39
DOI: 10.1108/IJPHM-12-2016-0066
Language: English
Journal: International Journal of Pharmaceutical and Healthcare Marketing

International Journal of Pharmaceutical and Healthcare Marketing

INT J PHARM HEALTHC

影响因子:1.1
是否综述期刊:否
是否OA:否
是否预警:不在预警名单内
发行时间:-
ISSN:1750-6123
发刊频率:-
收录数据库:ESCI/Scopus收录
出版国家/地区:-
出版社:Emerald

期刊介绍

年发文量 41
国人发稿量 1
国人发文占比 2.38%
自引率 9.1%
平均录取率 -
平均审稿周期 -
版面费 US$3370
偏重研究方向 HEALTH POLICY & SERVICES-
期刊官网 -
投稿链接 -

质量指标占比

研究类文章占比 OA被引用占比 撤稿占比 出版后修正文章占比
95.12% 1.83% - -

相关指数

影响因子
影响因子
年发文量
自引率
Cite Score

预警情况

时间 预警情况
2025年03月发布的2025版 不在预警名单中
2024年02月发布的2024版 不在预警名单中
2023年01月发布的2023版 不在预警名单中
2021年12月发布的2021版 不在预警名单中
2020年12月发布的2020版 不在预警名单中

JCR分区 WOS分区等级:Q4区

版本 按学科 分区
WOS期刊SCI分区
(2021-2022年最新版)
HEALTH POLICY & SERVICES Q4

中科院分区

版本 大类学科 小类学科 Top期刊 综述期刊
暂无数据